Emiliano Marco Navarra

Dr. Emiliano Marco Navarra


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2026 in Medicina
Verified
Journal Article
Open access
PDF file
DVDamiano Venturiello
Damiano Venturiello
GCGiuseppe Campolongo
Giuseppe Campolongo
ENEmiliano Marco Navarra
Emiliano Marco Navarra
GSGiuseppe Speziale
Giuseppe Speziale
Background and Objectives: Atrial secondary mitral regurgitation (A-SMR), also referred to as atrial functional mitral regurgitation, has emerged as a distinct clinical phenotype characterized by left atrial enlargement, mitral annular dilatation, and preserved left ventricular geometry and systolic function. Frequently associated with long-standing atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF), A-SMR challenges the traditional ventricular-centered classification of functional mitral regurgitation (MR) and is increasingly recognized as a clinically relevant condition. Materials and Methods: This narrative review provides an updated and critical overview of current evidence on A-SMR. We summarize available data on pathophysiology, diagnostic imaging, natural history, and therapeutic strategies, with particular emphasis on implications for cardiac surgery and clinical decision-making. Evidence was derived from observational studies, registry analyses, interventional reports, and contemporary guideline documents. Results: A-SMR is primarily driven by atrial remodeling and annular dilatation, with minimal contribution from ventricular distortion or leaflet tethering. Echocardiography and Magnetic Resonance Imaging (MRI) play a central role in diagnosis and phenotypic characterization, allowing differentiation from ventricular functional MR and identification of distinct A-SMR subtypes with potential therapeutic implications. A-SMR is a progressive condition associated with worsening symptoms and adverse clinical outcomes. Rhythm control strategies may reduce MR severity in selected patients by promoting atrial reverse remodeling. Transcatheter edge-to-edge repair (TEER) represents a treatment option for selected high-risk patients, although concerns regarding long-term durability remain in this predominantly annular disease. From a pathophysiological standpoint, surgical mitral valve repair based on annuloplasty directly targets the dominant mechanism of A-SMR and has been associated with favorable outcomes in appropriately selected patients. Conclusions: A-SMR is a distinct and increasingly recognized form of functional MR requiring a mechanism-oriented diagnostic and therapeutic approach. The 2025 ESC/EACTS Guidelines for the management of valvular heart disease have acknowledged A-SMR as a specific clinical phenotype, although dedicated phenotype-specific management recommendations remain limited. Surgical mitral valve repair, particularly when combined with AF ablation, represents a rational treatment strategy in selected patients and may improve long-term outcomes.

2 January 2026 in Medicina
Verified
Journal Article
Open access
PDF file
Walter VignaroliWalter Vignaroli
Walter Vignaroli
BPBarbara Pala
Barbara Pala
Giuseppe NassoGiuseppe Nasso
Giuseppe Nasso
SSStefano Sechi
Stefano Sechi
GCGiuseppe Campolongo
Giuseppe Campolongo
ENEmiliano Marco Navarra
Emiliano Marco Navarra
Over the past three decades, cardiac surgery has undergone a deep transformation, shifting from full median sternotomy to minimally invasive (MICS) and micro-invasive techniques. These approaches aim to achieve equivalent therapeutic outcomes while reducing surgical trauma, postoperative pain, hospitalization time, and healthcare costs. Minimally invasive strategies are now widely applied to aortic and mitral valve surgery, coronary artery bypass grafting, atrial fibrillation ablation, and combined procedures. Key advancements such as sutureless prostheses, video- and robotic-assisted systems, and enhanced imaging technologies have improved surgical precision and clinical outcomes while promoting faster recovery and superior cosmetic results. Evidence from randomized trials and observational studies demonstrates that MICS provides mortality and morbidity rates comparable to conventional surgery, with additional benefits in high-risk, elderly, and frail patients. Micro-invasive transcatheter interventions, particularly transcatheter aortic valve implantation (TAVI) and transcatheter mitral repair or replacement, have further expanded therapeutic options for patients unsuitable for open-heart surgery. Their success has fostered debate not between conventional and minimally invasive surgery, but between minimally invasive and micro-invasive approaches. Hybrid procedures—combining surgical and percutaneous techniques—exemplify a multidisciplinary evolution aimed at tailoring treatment to patient-specific anatomy, comorbidities, and risk profiles. Despite clear advantages, these techniques present challenges, including a steep learning curve, increased procedural costs, and the requirement for specialized equipment and institutional expertise. Optimal patient selection based on clinical risk assessment and advanced imaging remains essential. Future directions include refinement of robotic platforms, artificial intelligence-based decision support, miniaturization of instruments, and broader validation of emerging technologies in younger and low-risk populations. Minimally and micro-invasive cardiac surgery represent a paradigm shift toward patient-centered care, offering reduced physiological burden, improved functional recovery, and long-term outcomes comparable to conventional techniques. As innovation continues, these approaches are poised to become integral to modern cardiac surgical practice.

5 February 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
DVDamiano Venturiello
Damiano Venturiello
GCGiuseppe Campolongo
Giuseppe Campolongo
ENEmiliano Marco Navarra
Emiliano Marco Navarra
GSGiuseppe Speziale
Giuseppe Speziale
Background and Objectives Atrial secondary mitral regurgitation (A-SMR), also referred to as atrial functional mitral regurgitation, has emerged as a distinct clinical phenotype characterized by left atrial enlargement, mitral annular dilatation, and preserved left ventricular geometry and systolic function [1]. Frequently associated with long-standing atrial fibrillation and heart failure with preserved ejection fraction, A-SMR challenges the traditional ventricular-centered classification of functional mitral regurgitation and is increasingly recognized as a clinically relevant condition [2,3]. Materials and Methods This narrative review provides an updated and critical overview of cur-rent evidence on atrial secondary mitral regurgitation. We summarize available data on pathophysiology, diagnostic imaging, natural history, and therapeutic strategies, with particular emphasis on implications for cardiac surgery and clinical decision-making. Evidence was derived from observational studies, registry analyses, interventional reports, and contemporary guideline documents [4,5]. Results A-SMR is primarily driven by atrial remodeling and annular dilatation, with minimal contribution from ventricular distortion or leaflet tethering [1,3]. Echocardiography and Magnetic Resonance Imaging (MRI) play a central role in diagnosis and phenotypic characterization, allowing differentiation from ventricular functional mitral regurgitation and identification of distinct A-SMR subtypes with potential therapeutic implications [4]. A-SMR is a progressive condition associated with worsening symptoms and adverse clinical outcomes [2,3]. Rhythm control strategies may reduce mitral regurgitation severity in selected patients by promo-ting atrial reverse remodeling [6]. Transcatheter edge-to-edge repair (TEER) represents a treatment option for selected high-risk patients, al-though concerns regarding long-term durability remain in this predominantly annular disease [7]. From a pathophysiological standpoint, surgical mitral valve repair based on annuloplasty directly targets the dominant mechanism of A-SMR and has been associated with favorable outcomes in appropriately selected patients [8]. Conclusions Atrial secondary mitral regurgitation is a distinct and increasingly re-cognized form of functional mitral regurgitation requiring a mechanism-oriented diagnostic and therapeutic approach. 2025 ESC/EACTS Guidelines for the management of valvular heart disease have acknowledged A-SMR as a specific clinical phenotype, although dedicated phenotype-specific management recommendations remain limited [5]. Surgical mitral valve repair, particularly when combined with atrial fibrillation ablation, represents a rational treatment strategy in selected patients and may improve long-term outcomes [6,8].